J Thromb Haemost:血小板来源的微泡水平与静脉血栓栓塞风险相关

2022-01-21 MedSci原创 MedSci原创

该研究的结果表明,较高比例的PD微泡与未来发生VTE的风险相关,并提示血小板活化在VTE发病机制中的作用。

微泡是从细胞中脱落出来的较小的双膜封装颗粒。病例对照研究报道了静脉血栓栓塞(VTE)患者血浆中血小板来源的微泡(PD微泡)水平升高。然而,目前尚不清楚较高的PD微泡水平是否是急性VTE事件的危险因素或结局。

近日,血栓和凝血疾病权威杂志Journal of Thrombosis and Haemostasis上发表了一篇研究文章,该研究旨在明确血浆中PD微泡与未来发生VTE的风险之间的关联。

研究人员对314例VTE病例和705例年龄和性别匹配的对照者(来自Tromsø研究)进行了一项基于人群的嵌套病例对照研究,研究人员分析了血浆中PD微泡的比例(%)与未来静脉血栓栓塞事件风险之间的关联。研究人员从基线(即VTE发生之前)取样的血浆中分离出的微泡染上血小板标志物并通过流式细胞术进行分析。PD微泡的比例定义为PD微泡数量除以微泡的总数。研究人员根据PD微泡的比例不同四分位数估计了VTE风险的比值比(ORs)与95%置信区间(CI)。

与PD微泡的比例为最低四分位数的受试者相比,PD微泡的比例最高四分位数的受试者发生VTE的OR为1.78(95%CI为1.21-2.64),诱发的VTE为1.99(95%CI为1.24-3.26)。研究人员对年龄、性别、BMI、CRP、血小板计数和癌症进行了多变量调整后,该关联受到了中度程度的影响。当采血和VTE事件之间的时间较短时,VTE的OR较高。

由此可见,该研究的结果表明,较高比例的PD微泡与未来发生VTE的风险相关,并提示血小板活化在VTE发病机制中的作用。

原始出处:
 
Omri Snir.et al.Plasma levels of platelet-derived microvesicles are associated with risk of future venous thromboembolism.Journal of Thrombosis and Haemostasis.2022.https://onlinelibrary.wiley.com/doi/10.1111/jth.15638?af=R

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1698335, encodeId=12c7169833542, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Dec 05 06:31:04 CST 2022, time=2022-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955575, encodeId=63b319555e53d, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Aug 22 09:31:04 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008557, encodeId=6346200855eb9, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Mon Apr 11 03:31:04 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770105, encodeId=b5711e7010503, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Fri May 06 04:31:04 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614166, encodeId=6a2316141661e, content=<a href='/topic/show?id=35fd506241c' target=_blank style='color:#2F92EE;'>#微泡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50624, encryptionId=35fd506241c, topicName=微泡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cae519505912, createdName=124987cdm32暂无昵称, createdTime=Fri Jan 21 14:31:04 CST 2022, time=2022-01-21, status=1, ipAttribution=)]
    2022-12-05 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1698335, encodeId=12c7169833542, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Dec 05 06:31:04 CST 2022, time=2022-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955575, encodeId=63b319555e53d, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Aug 22 09:31:04 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008557, encodeId=6346200855eb9, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Mon Apr 11 03:31:04 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770105, encodeId=b5711e7010503, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Fri May 06 04:31:04 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614166, encodeId=6a2316141661e, content=<a href='/topic/show?id=35fd506241c' target=_blank style='color:#2F92EE;'>#微泡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50624, encryptionId=35fd506241c, topicName=微泡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cae519505912, createdName=124987cdm32暂无昵称, createdTime=Fri Jan 21 14:31:04 CST 2022, time=2022-01-21, status=1, ipAttribution=)]
    2022-08-22 xue8602
  3. [GetPortalCommentsPageByObjectIdResponse(id=1698335, encodeId=12c7169833542, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Dec 05 06:31:04 CST 2022, time=2022-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955575, encodeId=63b319555e53d, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Aug 22 09:31:04 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008557, encodeId=6346200855eb9, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Mon Apr 11 03:31:04 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770105, encodeId=b5711e7010503, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Fri May 06 04:31:04 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614166, encodeId=6a2316141661e, content=<a href='/topic/show?id=35fd506241c' target=_blank style='color:#2F92EE;'>#微泡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50624, encryptionId=35fd506241c, topicName=微泡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cae519505912, createdName=124987cdm32暂无昵称, createdTime=Fri Jan 21 14:31:04 CST 2022, time=2022-01-21, status=1, ipAttribution=)]
    2022-04-11 changfy
  4. [GetPortalCommentsPageByObjectIdResponse(id=1698335, encodeId=12c7169833542, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Dec 05 06:31:04 CST 2022, time=2022-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955575, encodeId=63b319555e53d, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Aug 22 09:31:04 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008557, encodeId=6346200855eb9, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Mon Apr 11 03:31:04 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770105, encodeId=b5711e7010503, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Fri May 06 04:31:04 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614166, encodeId=6a2316141661e, content=<a href='/topic/show?id=35fd506241c' target=_blank style='color:#2F92EE;'>#微泡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50624, encryptionId=35fd506241c, topicName=微泡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cae519505912, createdName=124987cdm32暂无昵称, createdTime=Fri Jan 21 14:31:04 CST 2022, time=2022-01-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1698335, encodeId=12c7169833542, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Dec 05 06:31:04 CST 2022, time=2022-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955575, encodeId=63b319555e53d, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Aug 22 09:31:04 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008557, encodeId=6346200855eb9, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Mon Apr 11 03:31:04 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770105, encodeId=b5711e7010503, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Fri May 06 04:31:04 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614166, encodeId=6a2316141661e, content=<a href='/topic/show?id=35fd506241c' target=_blank style='color:#2F92EE;'>#微泡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50624, encryptionId=35fd506241c, topicName=微泡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cae519505912, createdName=124987cdm32暂无昵称, createdTime=Fri Jan 21 14:31:04 CST 2022, time=2022-01-21, status=1, ipAttribution=)]

相关资讯

Am J Hematol:癌症住院患者静脉血栓栓塞风险 KS预测工具是否有效

静脉血栓栓塞(VTE)是一种需要住院患者重点预防的疾病;癌症的风险多样,而预防是一致的。既往证实的工具(Khorana评分,[KS])由5个容易获得的变量组成,可以确定门诊癌症患者的VTE风险,但该工具尚未在住院患者中研究过。2017年6月,发表在《Am J Hematol》的一项回顾性队列研究评价了KS预测癌症住院患者VTE风险的有效性。

Circulation: PCSK9抑制剂还能抗栓!

PCSK9抑制剂是一类新型降胆固醇药物。近期Circulation杂志发表的一项研究表明,PCSK9抑制剂可能还有抗栓功能。

J Thromb Haemost:看电视、体力活动与静脉血栓栓塞风险的关系

在考虑身体活动之前和之后,看电视与VTE风险之间没有关联。REGARDS中传统VTE危险因素的高负担可能掩盖了看电视与VTE之间的关联,或者看电视可能与VTE风险之间只存在一定程度的关联。